



REINSURANCE **HOT NEWS**

March 18, 2022

Clarification of CAR-T Cell Immunotherapy Billing

It has come to our attention that there is some confusion as to how the CAR-T Cell drug therapies, Kymriah (KYM), Yescarta (YES), and Tecartus (TEC) (hereafter [CAR-T Drug]) should be billed. The transplant specialty contract states the following in regards to these drugs:

“The [CAR-T Drug] will be reimbursed through the contract when administered **in an inpatient setting only** and is available for purchase through the 340B Drug Pricing Program for the treatment of both pediatric and adult patients with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. The [CAR-T Drug] will be billed with Q code QXXXX or QYYYY. **[CAR-T Drug] administered in an outpatient setting will be reimbursed outside of the Transplant Contract.**”

To clarify, for transplant reimbursement, CAR-T Drugs must be administered in an inpatient setting and billed as a carve out on an **inpatient UB with only the drug codes.**

